blind, randomized, placebo-controlled clinical trial

 

Results from Brazil Public Health System, one year on. 

Out of the 600 children recruited, 445 completed the study.149: Homeopathic complex; 151: Placebo; 145: hom  InfluBio.

In the first year post-intervention, there was no episode in the group of 149 children who used Homeopathic Complex, and only 1 episode in the group of 145 (1%) children who received homeopathic InfluBio.

46/151 (30.5%) of children in the placebo group developed 3 or more flu and acute respiratory infection episodes, during the year after the start of the study.

Of the 600 children selected for the study, 445 (74.17%) children finished it and 155 (25.83%) children were classified as dropouts, since they quit during the research period. The main reasons for this loss were change of residence or adhesion to private health insurance plans (Figure 1). An important fact to be mentioned is that no child died during the study.

Homeopathy is completely different to any other type of healing modality. There is energy of a material dose is homeopathy. Matter diluted and added to water, is homeopathy. The energy changes the body, mind and emotions of a person, so that the body can realign to a naturally healthy alternative to the disease that is present now.

Acknowledgments

This work was partly sponsored by FAPERJ and Instituto Roberto Costa, and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) granted Camila Monteiro Siqueira with a PhD scholarship. We thank to the professionals and families who participated in this clinical trial.

Author

Camila Monteiro Siqueira 1 2, Fortune Homsani 1, Venício Féo da Veiga 3, Carlos Lyrio 4, Haroldo Mattos 5, Sonia Regina Lambert Passos 6, José Nelson Couceiro 3, Carla Holandino Quaresma 1

Thai Hospital  Covid 

 In late June 2020, The Nation Thailand reported that phase 1 of the Thai research initiative on Andrographis for COVID-19 had begun at two hospitals in Thailand, six subjects.

In late August 2020, The Nation Thailand reported that the lower dose of andrographis showed benefits in the preliminary trial, especially for coughing. Within three days, both cough volume and overall symptom severity reportedly decreased significantly.

After five days, other symptoms improved, and real-time polymerase chain reaction (PCR) tests were negative for the COVID-19 virus in two patients.

After three weeks, real-time PCR tests were negative in all six subjects, but additional studies were needed to confirm the results.

There are a lot of research studies ongoing around the world, Kan jang or andrographus is a very powerful herb, and helps when ever I have a flu.

You can google thai hospital and covid for a copy of the study.

Italian Research homeopathy and Covid 

 The initiative of SIMO – Italian Society of Homeopathic Medicine (www.omeomed.net). Italian Study Results on Homeopathic Treatment of 50 COVID-19 Patients None of Whom Needed Hospitalization. Symptomatic COVID-19 positive and likely patients treated by homeopathic.

The level of hospitalization is one of the key factors in assessing the ability of the health care system to respond to the epidemic. The recent ECDC report states: “Hospitalization occurred in 32% 48,755 of 152,375 of cases reported from 26 countries.

In Italy, the bulletin on the Covid-19 epidemic of March 30, 2020 produced by the Istituto Superiore di Sanità writes: “Information on the place of treatment is available for 88,257 cases (about 70.8% of total cases). Currently 18,047 cases (20.4%) are hospitalized and of these 2,734 (18.7%) are hospitalized in intensive care”.(10)

Therefore, the purpose of this study was to evaluate the level of hospitalization of Covid-19 patients treated by doctors with additional expertise in homeopathy. 

From 25 February to 7 April 2020 we collected 50 symptomatic case reports in home isolation, positive or probable COVID-19, followed by the family doctor and, since the patients requested it, also by a physician expert in homeopathy. The patients were in isolation in different Italian locations.

A total of 24 homeopaths were involved. They are clinicians with extensive experience in homeopathy and are all registered in the lists of homeopathic medical experts with the respective Orders of Physicians and Surgeons. Each doctor involved in the project was required to send all consecutive cases under treatment, whatever the outcome of the treatment implemented.

RESULTS:

We publish the results of the 50 individual cases received corresponding to the inclusion criteria, evaluated at the end of the treatment without waiting for a further follow-up.

The 50 cases examined consisted of 29 females and 20 males. (one not gender specified). The cases observed were between 6 and 79 years old; their course (varying from 4 to 34 days) was 14.09 days on average

In each individual case only one single-component homeopathic medicinal product has been diagnosed and prescribed at a time with only one potency, chosen individually according to the symptoms presented. This is traditional Homeopathy.

No adverse events were observed during homeopathic treatments. An overall recovery of patients at resolution of specific symptoms has been commonly observed.

Austrian Icu research Covid clinical trial

 

Austria lets Homoepathy into the Icu

In Austria in the ICU, 13 patients were treated with Homeopathy. 12 left hospital with out needing further treatment, after this study.

One had gangrene from a chair falling on them and being found 4 days later with sepsis. This one with advanced stage of septic disease died in hospital.

The following is one case only in ICU. Please google the above heading for the whole study.

Case 4, Infection with SARS-CoV-2 was confirmed in a 59-year-old male patient on March 19th, 2020. The patient presented with a headache, irritable cough, aching limbs and fever. Previous illnesses include diabetes mellitus type II, arterial hypertension, left ventricular hypertrophy, hyperlipidemia, transient ischemic attack, left hemicolectomy due to a perforated diverticulitis in 2003, facial herpes simplex, and a cyst on the left submandibular side.

After three weeks in Icu with no change, the Doctor switched to Homeopathy.

Homeopathic therapy in ICU started on April 6th

A progressive weaning from the respirator was implemented on April 7th.

On April 9th. a substantial amelioration of dyspnea with a significant decrease of the pulmonary infiltrates was found.

The patient could be extubated on April 11th.

On April 18th. The patient could be transferred to the general inpatient ward.

The patient was discharged home after two negative SARS-CoV-2 swabs on April 22nd, 2020

Here are the details of the study

Adjunctive homeopathic treatment of hospitalized COVID-19 patients
(COVIHOM): A retrospective case series
Michael Takacsa, Michael Frassb,c,d,e,*, Gernot Walderf, Philippa Fibertg, Maria Rottensteinerc,
Walter Glückc, Peter Lechleitnera, Menachem Oberbaumh, Ilse Leisseri, Kavita Chandakj,
Peter Panhoferc,d,k,l, Petra Weiermayerb

300 people covid placebo-controlled clinical trial

A randomized, placebo-controlled trial of adjunct homeopathy with standard of care for COVID-19 was conducted on 300 patients in a hospital environment. India Chirayu hospital

• Primary outcome on total symptom score measured over 10 days decreased significantly favoring Standard of care + Homeopathy.

• Recovery was earlier in Standard of care + Homeopathy group by 02 days showing the added benefits of homeopathy.

• Resolution of fever was 20 hours earlier in Standard of care + Homeopathy SC+H

• The study was conducted between July 2020 and October 2020.

• Patients who were reverse transcription polymerase chain reaction (RT-PCR) positive for SARS-CoV-2 and admitted to the COVID-19 ward of Chirayu Hospital were screened for study eligibility. Symptomatic patients aged 18–80 years, both sexes, willing to give written informed consent were included in the study

• All patients received supportive care according to the standard of care of the hospital as per the prevailing recommendation of the state government for COVID-19. It consisted of azithromycin 500 mg (once daily), pantaprazole 40 mg (once daily), calcium 500 mg (twice daily), Montelukast 10 mg/Levicetirizin 5 mg (once daily, during hours of sleep), Zinc 50 mg (once daily), vit D3 60000 IU (weekly). This regimen of standard care was given for 5 days. However, this protocol was modified as per the requirement and patient prognosis. Medicines were also given for symptomatic management of cough and pain, etc. as per the symptoms of the patient. Anti-hypertensive, anti-diabetic and others were given to patients as per the need of the individual case.

• Of the 300 consenting adults there were N=151 in the SC+H group and N=149 in the placebo group SC+P

Each symptom’s severity was measured on a 10-point numerical rating patient-reported scale. The patients were asked by the homeopathic treating physicians to rate their symptoms experienced over the past 24 h, 0 being no symptom to 10 being the worst suffering from the symptom imaginable. The score of each symptom was added to get the total symptom score for each patient. The outcome was assessed every day between 8 a.m. and 12 noon.

The secondary outcomes were time to fever clearance and time to clinical recovery. Time to fever clearance was defined as the time from the first dose of the study drug until the temperature dropped to ≤37.5 °C and remained below this temperature for at least 48 h. The body temperature of patients was recorded every 6 h. Time to clinical recovery was the time from enrolment till the total symptom score became ‘0’.

Assuming a 10% withdrawal rate, a total of 305 patients were needed for enrolment

The homeopathic medicines were dispensed through medicated sucrose pills; similarly, the placebo group received sucrose pills impregnated with ethyl alcohol. Both medicated and placebo pills were identical in colour, odour, and appearance.

The symptoms (dyspnoea, sputum production, fatigue, cough, headache) which were frequently associated with adverse outcomes in COVID-19 patients were analyzed for the percentage of patients getting relieved from them. The day-wise cumulative percentage was calculated for the no. of patients who had resolution of each pathogonomic symptom. A P value less than 0.05 was considered statistically significant

The most common comorbidity was hypertension followed by diabetes mellitus and chronic lung disease. At the time of enrolment 62.91% (n = 95) had pneumonia in the SC + H group, while 51% (n = 76) had pneumonia in the SC + P group. Among all the patients, 1.39% (n = 2) had oxygen saturation below 90%, 27.27% (n = 39) had between 90% and 95% in the SC + H group and 3.54% (n = 5) had oxygen saturation below 90%, 28.36% (n = 40) had between 90%–95% in the SC + P group. The patients were classified into mild, moderate, and severe as per the presentation at baseline.

Outcome

After 5 days of treatment, a significant number of patients in the SC + H group got rid of symptoms. Placebo being /SC+P. The cumulative percentage of patients getting relieved of symptoms is as follows (SC + H/SC + P): dyspnoea 60.66%/29.73%; sputum production 85.29%/21.05%; fatigue 68.57%/21.82%; cough 64.63%/33.33%; headache 84.09%/78.13%.

Our study found that adjunct individualized homeopathic medicine with the standard of care significantly improves clinical recovery with early resolution of symptoms compared to those who received placebo along with the standard of care. This study is the first of its kind with adjunct individualized homeopathic treatment of COVID-19.

About 82% of post-COVID-19 patients reported suffering from at least one symptom related to COVID-19 [21]. In our study in the standard care group, 63% had at least one symptom at the time of discharge from the hospital. However, in the adjunct treatment group, only 24% of patients had any residual symptom related to COVID-19 at discharge from the hospital.

Adjunct homeopathy could significantly shorten the time for fever clearance, thereby reducing the need for antipyretics. It has been reported that symptoms such as dyspnoea, sputum production, fatigue, and headaches are frequently observed in patients with fatal outcomes [22]; however, in our study, these symptoms resolved earlier in patients who received adjunct homeopathy than in those who received standard of care only.

Symptoms related to pneumonia were resolved earlier in the SC + H group than in the SC + P group.

Due to the large number of COVID-19 patients during the study at the hospital, the follow-up laboratory tests of all the patients could not be done due to a resource crunch. However, this does not limit the applicability of the study results as clinical improvement is evident from an early resolution of symptoms of the patients.

The no. of moderate/severe (based on the presence of pneumonic changes in the lung) cases and patients having higher total symptom scores at baseline were more in the SC + H group, however there were more in the homeopathic group than the placebo group in chronic lung cases.

The study was created by homeopaths;

Debadatta Nayak a, Juhi Gupta b, Anupriya Chaudhary c, Krishna  Gopal Singh d, Abhijeet Deshmukh e, Deblina Das a, Abhishek Saha f, Deepak Kumar a, Ashwini Kumar a, Ajay Goenka g, S.K. Mishra h, Sanjay Gupta i, Anil Khurana j

Cost–benefit evaluation of homeopathic versus conventional therapy in respiratory diseases

Author links open Elio Rossi , Lara Crudeli , Cristina Endrizzi , Danila Garibaldi 

https://doi.org/10.1016/j.homp.2008.11.005Get rights and content

Methods

A retrospective observational study was conducted on 105 out of 233 patients suffering from chronic respiratory disease attending the Homeopathic Clinic of the Campo di Marte Hospital in Lucca (Tuscany, Italy) between October 1998 and May 2003. We assessed the cost of conventional medicinal products using Anatomic Therapeutic Chemical (ATC) classification, specific for the pathology in question, and the general costs in the year preceding the first appointment at the Homeopathic Clinic vs. the first and second year subsequent to homeopathic treatment. The costs of conventional drugs for a group of patients affected by asthma (8 patients) and recurrent respiratory infections (16 patients) with long term use of conventional medicine treated by homeopathy were compared with the expenses of conventional drugs of a matched group of 16 and 32 patients, respectively.

Results

Costs of pharmacological therapy specific for respiratory diseases were reduced by 46.3% (n = 105) in the first year (P < 0.01); and by 47.5% (n = 72) in the second year (P < 0.01) of homeopathic treatment. Reduction in general drug costs during homeopathic therapy was 42.4% in the first year (P < 0.01); and −49.8 in the second year (N.S.). Costs for patients affected by chronic asthma showed a reduction in expenses of 71.1% for specific medicines relative to the group in homeopathic treatment vs. an increase of 12.3% in the group treated only with conventional drugs after the first year of follow-up and, respectively, a reduction of −54.4% for homeopathic treatment vs. +45.2% after the second year. For patients with recurrent respiratory infections we found a reduction of 35.8% in the homeopathic group in the first year, compared to an increase 8.6% of costs for specific drugs in the control group; in the second year the respective figures were −43.6% versus +7.8% in the control group.

Conclusions

Homeopathic treatment for respiratory diseases (asthma, allergic complaints, Acute Recurrent Respiratory Infections) was associated with a significant reduction in the use and costs of conventional drugs. Costs for homeopathic therapy are significantly lower than those for conventional pharmacological therapy.